“EEMs and exosomes each have attractive characteristics as therapeutics,” Dr. Hematti, UW-Madison’s Department of Medicine, noted.” As a cell therapy, EEMs will not proliferate or differentiate to undesirable cell types, which remains a concern for many stem cell therapies. Moreover, EEMs could be generated from a patient’s own monocytes using off-the-shelf exosomes, resulting in a faster and more facile process compared to autologous MSCs. Alternatively, exosome therapy could be a cell free, shelf-stable therapeutic to deliver biologically active components.” “Altogether, we believe our studies’ results support the use of EEMs and/or exosomes to improve ligament healing by modulating inflammation and tissue remodeling,” Dr. Vanderby concluded.
November 3, 2020
Read the full article at: https://www.eurekalert.org/pub_releases/2020-11/ap-spw110220.php